Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Carvedilol & Heart Failure / Congestive heart failure (CHF)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Carvedilol is approved by both the FDA and EMA for treating Heart Failure / Congestive heart failure (CHF) with reduced ejection fraction, in the context of Carvedilol & Heart Failure/Congestive Heart Failure (CHF) (1, 2)

Carvedilol is a medication that plays a significant role in the management of Heart Failure / Congestive heart failure (CHF).

Baseline predictors of tolerability to carvedilol in patients with chronic heart failure
Krum et al. 2000 Heart 84(6): 615-9
Carvedilol in the failing heart
Lombardi & Gilbert 2001 Clin Cardiol 24(12): 757-66
Review
Carvedilol Inhibits Clinical Progression in Patients With Mild Symptoms of Heart Failure
Colucci et al. 1996 Circulation 94: 2800-2806
Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure
Packer et al. 1996 Circulation 94(11): 2793-2799
Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study
Krum et al. 2003 JAMA 289(6): 712-718
Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis
Karwath et al. 2021 The Lancet 398: 1427
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer et al. 1996a N Engl J Med 334: 1349-1355

7/1/2026